Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biocryst Pharma Inc (BCRX)

Biocryst Pharma Inc (BCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,126,792
  • Shares Outstanding, K 250,801
  • Annual Sales, $ 874,840 K
  • Annual Income, $ 263,860 K
  • EBIT $ 341 M
  • EBITDA $ 338 M
  • 60-Month Beta 0.74
  • Price/Sales 2.44
  • Price/Cash Flow 6.87
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 72.60% (+12.25%)
  • Historical Volatility 43.80%
  • IV Percentile 81%
  • IV Rank 29.32%
  • IV High 167.17% on 02/04/26
  • IV Low 33.36% on 08/26/25
  • Expected Move (DTE 11) 0.75 (8.68%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 5,046
  • Volume Avg (30-Day) 1,804
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 42,045
  • Open Int (30-Day) 40,511
  • Expected Range 7.87 to 9.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.06
  • Number of Estimates 4
  • High Estimate 0.10
  • Low Estimate 0.02
  • Prior Year 0.00
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.30 +36.83%
on 02/10/26
8.86 -2.71%
on 03/03/26
+2.32 (+36.83%)
since 02/09/26
3-Month
6.23 +38.36%
on 02/05/26
8.86 -2.71%
on 03/03/26
+0.98 (+12.83%)
since 12/09/25
52-Week
6.00 +43.67%
on 10/14/25
11.31 -23.78%
on 06/04/25
+0.93 (+12.09%)
since 03/07/25

Most Recent Stories

More News
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., March 04, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the compensation committee of BioCryst’s board of directors granted...

BCRX : 8.62 (+1.65%)
BioCryst: Q4 Earnings Snapshot

BioCryst: Q4 Earnings Snapshot

BCRX : 8.62 (+1.65%)
BioCryst Reports Full Year 2025 Financial Results and Provides Business Update

—Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A....

BCRX : 8.62 (+1.65%)
BioCryst to Present at Upcoming Investor Conference

RESEARCH TRIANGLE PARK, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the T.D. Cowen 46 th Annual Health...

BCRX : 8.62 (+1.65%)
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting

RESEARCH TRIANGLE PARK, N.C., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present nine abstracts from its hereditary angioedema...

BCRX : 8.62 (+1.65%)
BioCryst to Report Fourth Quarter 2025 Financial Results on February 26

RESEARCH TRIANGLE PARK, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2025 financial results...

BCRX : 8.62 (+1.65%)
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted...

BCRX : 8.62 (+1.65%)
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema 

RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has completed its acquisition of Astria Therapeutics, Inc., initially...

BCRX : 8.62 (+1.65%)
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range

–Excluding European ORLADEYO revenue for the full year 2025, preliminary 2025 ORLADEYO net revenue was $563 million (+43 percent y-o-y on a comparable basis)– –ORLADEYO net revenue expected...

BCRX : 8.62 (+1.65%)
Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

NEW YORK and NEW ORLEANS , Jan. 7, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC ("KSF") are investigating the...

ATXS : 12.58 (+0.64%)
BCRX : 8.62 (+1.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strengthening short term outlook on maintaining the current direction.

Relative Strength just crossed above 70%. The market has entered overbought territory.

See More Share

Business Summary

BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential...

See More

Key Turning Points

3rd Resistance Point 9.00
2nd Resistance Point 8.83
1st Resistance Point 8.73
Last Price 8.62
1st Support Level 8.45
2nd Support Level 8.28
3rd Support Level 8.18

See More

52-Week High 11.31
Fibonacci 61.8% 9.28
Fibonacci 50% 8.66
Last Price 8.62
Fibonacci 38.2% 8.03
52-Week Low 6.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar